538965 Stock Overview
Concord Drugs Limited manufactures and sells pharmaceutical formulations in India.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 3/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Concord Drugs Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹35.17 |
52 Week High | ₹61.50 |
52 Week Low | ₹25.56 |
Beta | 0.37 |
1 Month Change | -11.07% |
3 Month Change | -41.11% |
1 Year Change | 30.65% |
3 Year Change | 15.31% |
5 Year Change | 61.33% |
Change since IPO | 75.94% |
Recent News & Updates
Recent updates
Shareholder Returns
538965 | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | -0.2% | 2.7% | 2.5% |
1Y | 30.6% | 63.9% | 47.3% |
Return vs Industry: 538965 underperformed the Indian Pharmaceuticals industry which returned 63.9% over the past year.
Return vs Market: 538965 underperformed the Indian Market which returned 47.3% over the past year.
Price Volatility
538965 volatility | |
---|---|
538965 Average Weekly Movement | 7.4% |
Pharmaceuticals Industry Average Movement | 5.9% |
Market Average Movement | 6.6% |
10% most volatile stocks in IN Market | 10.1% |
10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 538965's share price has been volatile over the past 3 months.
Volatility Over Time: 538965's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | 185 | Seelam Reddy | https://www.concorddrugs.in |
Concord Drugs Limited manufactures and sells pharmaceutical formulations in India. It offers drugs in the form of tablets, capsules, small volume parenterals, dry powders, dry syrups, and liquid orals, as well as ready-to-fill pellets and multiple unit pellets system. The company was incorporated in 1995 and is based in Hyderabad, India.
Concord Drugs Limited Fundamentals Summary
538965 fundamental statistics | |
---|---|
Market cap | ₹351.70m |
Earnings (TTM) | ₹9.74m |
Revenue (TTM) | ₹415.89m |
36.1x
P/E Ratio0.8x
P/S RatioIs 538965 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
538965 income statement (TTM) | |
---|---|
Revenue | ₹415.89m |
Cost of Revenue | ₹313.76m |
Gross Profit | ₹102.13m |
Other Expenses | ₹92.39m |
Earnings | ₹9.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 30, 2024
Earnings per share (EPS) | 0.97 |
Gross Margin | 24.56% |
Net Profit Margin | 2.34% |
Debt/Equity Ratio | 52.3% |
How did 538965 perform over the long term?
See historical performance and comparison